Related Experiment Videos

The CARDS trial: diabetic patients dealt a winning hand

Annemarie Armani1, Peter P Toth

  • 1Sterling Rock Falls Clinic, 101 East Miller Road, Sterling, IL 61081, USA.

Current Atherosclerosis Reports
|August 12, 2006
PubMed

Insights

Statin therapy, specifically atorvastatin, significantly reduces cardiovascular events in diabetic patients without existing heart disease. This finding highlights the importance of early intervention with statins for primary cardiovascular event prevention in this population.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • The role of statin therapy in diabetic patients lacking coronary heart disease symptoms was previously unclear.
  • Diabetes is a significant risk factor for cardiovascular disease.

Purpose of the Study:

  • To evaluate the efficacy of atorvastatin in preventing primary coronary events in diabetic individuals without clinical coronary heart disease.
  • To assess the impact of atorvastatin on major adverse cardiovascular events, acute coronary events, revascularizations, and stroke.

Main Methods:

  • Prospective, randomized, placebo-controlled trial (Collaborative Atorvastatin Diabetes Study - CARDS).
  • Involved diabetic patients without established coronary heart disease.
  • Median follow-up of 3.9 years, with early termination due to observed benefits.

Main Results:

  • Atorvastatin reduced the risk of major cardiovascular events by 37%.
  • Significant reductions observed in acute coronary heart disease-related events (36%), coronary revascularizations (31%), and stroke (48%).
  • Therapeutic benefits of atorvastatin became evident within the first year of treatment.

Conclusions:

  • Atorvastatin therapy provides substantial primary prevention benefits against cardiovascular events in diabetic patients.
  • Early initiation of atorvastatin is crucial for mitigating cardiovascular risk in this high-risk group.
  • The CARDS trial demonstrated a clear and significant benefit of atorvastatin therapy, leading to its early termination.

Related Concept Videos

Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
Diabetic Neuropathy01:22

Diabetic Neuropathy

DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetic Foot Ulcer01:31

Diabetic Foot Ulcer

Definition A diabetic foot ulcer (DFU) is a chronic, non-healing wound that develops in individuals with diabetes. It typically occurs on pressure-bearing areas such as the heel, metatarsal heads, or hallux, and carries a high risk of infection and amputation.Pathophysiology • The development of DFUs can be explained by four interconnected mechanisms: neuropathy, ischemia, infection, and impaired wound healing. • Neuropathy is the most common factor. Sensory neuropathy reduces pain perception,...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...